Nexavar case may spawn more India compulsory licensing activity in oncology/HIV areas
This article was originally published in Scrip
India's recent decision granting a compulsory licence for Bayer's anticancer Nexavar (sorafenib tosylate) to Natco Pharma may theoretically open the flood gates to several more applications, especially in the oncology and HIV/AIDS segments. But legal experts believe that the controversial interpretation of "working" an invention to include local manufacture may be challenged all the way to the country's top court or even at the World Trade Organisation (WTO).
You may also be interested in...
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.